Genmab A/S
GNMSF
$310.63
-$0.88-0.28%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 26.33% | 26.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 26.33% | 26.33% |
| Cost of Revenue | -- | -- | -- | 126.93% | 126.93% |
| Gross Profit | -- | -- | -- | 23.14% | 23.14% |
| SG&A Expenses | -- | -- | -- | 15.41% | 15.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | 20.98% | 20.98% |
| Operating Income | -- | -- | -- | 37.83% | 37.83% |
| Income Before Tax | -- | -- | -- | 35.08% | 35.08% |
| Income Tax Expenses | -- | -- | -- | -37.83% | -37.83% |
| Earnings from Continuing Operations | -- | -- | -- | 61.17% | 61.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | 61.17% | 61.17% |
| EBIT | -- | -- | -- | 37.83% | 37.83% |
| EBITDA | -- | -- | -- | 37.28% | 38.16% |
| EPS Basic | -- | -- | -- | 66.02% | 66.02% |
| Normalized Basic EPS | -- | -- | -- | 32.00% | 32.00% |
| EPS Diluted | -- | -- | -- | 66.18% | 66.18% |
| Normalized Diluted EPS | -- | -- | -- | 32.16% | 32.16% |
| Average Basic Shares Outstanding | -- | -- | -- | -2.86% | -2.86% |
| Average Diluted Shares Outstanding | -- | -- | -- | -3.06% | -3.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |